Paxil TV Ad Case Could Produce Ruling On FDA’s Authority To Regulate Ads
Executive Summary
A suit regarding claims in Paxil TV ads could produce a court ruling regarding FDA's authority to regulate advertising
You may also be interested in...
Paxil product liability claims
GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...
Paxil product liability claims
GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...
GSK Paxil CR Ad Medicalizes “Ordinary” Anxiety, FDA Says
GlaxoSmithKline Paxil CR TV ads suggest the antidepressant is appropriate for treating anxiety that does not require medication, FDA's ad division says